Joseph Sheehey (Courtesy photo)
(This is a contributed guest column. To be considered as an MJBizDaily guest columnist, please submit your request here.)
In just a few short years, hemp‑derived cannabinoids have surged from a niche curiosity to a $28 billion market, flourishing in a regulatory gray zone that sparked both innovation and uncertainty.
That era of loosely supervised growth is drawing to a close.
State regulators are scrutinizing how hemp‑derived THC beverages, edibles and topicals are made, sold and advertised, but the most consequential shift is coming from Washington.
On November 12, federal law will redefine hemp, introducing a total‑THC ceiling and strict limits on the amount of cannabinoids allowed in finished products.
While some commentators predict an outright ban, most experts anticipate a framework of clear rules—a development that calls for preparation, not panic.
What does the future hold for hemp‑derived THC in the United States?
Under the new definition, “hemp” will encompass only cannabis products containing no more than 0.3 % total THC, a figure that now includes THCA as well as delta‑9 and delta‑8 forms. Finished goods will be limited to a maximum of 0.4 mg of THC per consumer container; anything above that threshold will no longer qualify as federally legal hemp.
Meanwhile, states continue to chart their own courses, and a recent bipartisan Senate proposal would let individual states opt out of certain portions of the forthcoming federal regime.
This regulatory flux creates genuine uncertainty for businesses. Formulation, packaging, labeling, distribution and cross‑state retail availability will all feel the impact.
Companies that begin reviewing their product recipes, container designs, label copy and logistics now will avoid the scramble of last‑minute reformulations, discontinued SKUs or blocked market access when enforcement begins.
The long‑term viability of the hemp sector will hinge on the industry’s ability to adopt transparent standards for dosage, testing, labeling and consumer safety.
How will the updated Farm Bill change the THC calculation for hemp?
The update replaces the old delta‑9‑only test with a broader total‑THC measurement that aggregates delta‑9 THC, delta‑8 THC, THCA (after decarboxylation) and other THC isomers or analogs.
Consequently, many products that previously slipped under the 0.3 % delta‑9 limit may now exceed the new total‑THC cap and lose their federal hemp status.
The revised standard covers:
- Delta‑9 THC
- Delta‑8 THC
- THCA (post‑decarboxylation)
- Other THC isomers and analogs
Regulators face a thorny challenge: deciding what amount of THC is permissible without lumping low‑dose wellness items together with high‑potency intoxicants.
Past debates have often leaned on simple, blanket limits that ignore how consumers actually use these products.
A smarter path ties regulation to dosage rather than fear, recognizing that a modest amount of THC can serve a functional purpose without causing impairment.
What constitutes an appropriate THC dose?
Research from Johns Hopkins University demonstrates that THC’s effects are dose‑dependent; low doses typically produce no measurable impairment, whereas higher amounts do.
This evidence supports a regulatory model that distinguishes products by intent and serving size.
A low‑dose tincture aimed at stress relief or sleep support is fundamentally different from a high‑dose edible designed for recreation.
Applying a uniform cap of 0.3 % THC by weight or 0.4 mg per container forces both categories into the same box, needlessly restricting access for consumers who seek only subtle wellness benefits.
A dosage‑based framework would preserve safety while allowing legitimate, functional products to remain on the market.
Without such nuance, upcoming federal rules could mistakenly treat a 2 mg functional supplement the same as a potent intoxicating product, despite clear differences in user intent and physiological impact.
How can hemp‑THC operators act responsibly?
If regulation is to lend legitimacy to the sector, it must begin with consistency and transparency.
That means enforcing age limits for every THC‑containing item, even those with minimal potency; adopting child‑resistant packaging that matches real‑world usage patterns; and demanding full supply‑chain visibility backed by rigorous third‑party testing.
The hemp industry is uniquely positioned to set a higher bar.
Today’s supplement market often lacks the testing and accountability consumers expect; hemp brands can close that gap, building trust and securing long‑term credibility.
Without these safeguards, bad actors will continue to cut corners, exposing the entire sector to reputational and legal risk.
Why does the broader cannabis industry need hemp‑derived THC?
Although the regulated marijuana and hemp markets have sometimes clashed, there is a compelling reason to collaborate.
Despite growing acceptance of THC, a sizable portion of the public will never step into a dispensary.
That does not mean they lack interest in cannabinoids. Many consumers already incorporate full‑spectrum CBD paired with low‑dose THC into their daily routines to ease stress, improve sleep or support overall wellness.
For this group, easy access is essential. We see this dynamic playing out in state capitals—most recently in Texas, where lawmakers floated a hemp restriction that would have curbed availability of hemp‑derived cannabinoids. Although the proposal has been paused, it signals a wider trend of states acting independently to shape the market ahead of federal enforcement.
Texas is not an isolated case; numerous states are now moving to limit or ban certain hemp cannabinoids, creating a patchwork of rules that complicates multi‑state operations.
Subscribe to the MJBiz Factbook
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype.
What you will get:
- Monthly and quarterly updates, with new data & insights
- Financial forecasts + capital investment trends
- State-by-state guide to regulations, taxes & market opportunities
- Annual survey of cannabis businesses
- Consumer insights
- And more!
Why e‑commerce remains vital for hemp‑THC brands
Online sales have been a lifeline for reaching consumers who value privacy, convenience and a low‑pressure shopping experience—advantages that brick‑and‑mortar stores often cannot match.
As regulators tighten rules, preserving a compliant direct‑to‑consumer channel will be crucial.
If that avenue disappears, the industry does not merely forfeit revenue; it loses an entire segment of customers seeking a different relationship with cannabis.
With the November 2026 compliance deadline looming and federal agencies drafting enforcement guidance, the window for proactive adaptation is narrowing.
Businesses that adopt transparent standards, dosage‑based labeling, and consumer‑first access models now will be best equipped to thrive under the upcoming regime.
The companies most likely to navigate the transition successfully are those preparing today for a compliance‑focused marketplace, rather than relying on the ambiguity that has characterized the past few years.
A former NASA contributing aerospace engineer, Joseph Sheehey is the founder and CEO of Colorado‑based cannabinoid wellness brand Cured Nutrition.
